Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + azacitidine
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
sorafenib + azacitidine is a combination therapy being evaluated for the treatment of FLT3-ITD mutated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This regimen, notably studied in Phase II trials at the M.D. Anderson Cancer Center, combines the hypomethylating agent azacitidine with the multi-kinase inhibitor sorafenib. Azacitidine works as a DNA methyltransferase inhibitor, which can induce the expression of silenced genes and potentially sensitize cells to other therapies. Sorafenib targets several kinases, most importantly the FLT3-ITD mutation, which is associated with poor prognosis in AML. The combination has shown promising clinical activity, particularly in older patients or those ineligible for intensive chemotherapy.
- Brand names
- Nexavar
- Other names
- 5-azacitidine + sorafenibazacitidine + sorafenibVidaza + Nexavarazacytidine + sorafenib
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)5-HT2C (5-hydroxytryptamine receptor 2C)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on sorafenib + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + azacitidine.